| Heading: |
Brain: Tumours |
| Question ID: |
1783457 |
| UIN: |
37460 |
| House: |
Commons |
| Date tabled: |
2025-03-11 |
| Asking Member ID: |
5256 |
| Asking Member display name: |
Jonathan Davies
|
| Asking Member handle: |
Jonathan4MD
|
| Asking Member Twitter reference: |
@Jonathan4MD
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of including nanopore sequencing-based brain tumour methylome classification in the National Genomic Test Directory. |
| Is named day: |
true |
| Date of holding answer: |
2025-03-18 |
| Date answered: |
2025-03-24 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department funded the Cancer 2.0 initiative in 2021, delivered by Genomics England in close partnership with NHS England. The three-year programme demonstrated that nanopore sequencing-based brain tumour classification demonstrates significant promise... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |